Matthew Seftel, MD, MPH, FRCP, FRCPC
Head, Department of Medical Oncology and Hematology, CancerCare Manitoba
Associate Professor, Section of Hematology/Oncology, Department of Internal Medicine, University of Manitoba
For diseases caused by inherited or acquired genetic mutations, the ideal remedy is to correct the relevant mutations. Recently, promising results have emerged about gene therapy for patients with inherited conditions as well as in patients with acquired hematological malignancies, with positive results for the latter being obtained by infusing chimeric antigen receptor T-cell therapy (CART). Using CART as the most prominent example of gene therapy, this talk will provide a background to gene therapy and to blood and marrow transplantation. Dr. Seftel will summarize the available data about CART therapy and will also outline the clinical, economic, and regulatory challenges associated with CART and other gene therapeutics.
There is no fee to participate, but you must register to attend or to watch the live stream of the event.
Date: Tuesday, February 27, 2018
Lecture: 2:00 p.m. to 3:00 p.m. EST
Reception: 3:00 p.m. to 3:30 p.m. EST
In person: Dows Lake Court Conference Centre, 865 Carling Avenue, Ottawa
Online: Information to access the live stream broadcast will be provided after registration, closer to the event date.
Feel free to distribute this invitation within your networks. We sincerely hope you and your colleagues can join us. If you have any questions about the lecture or how to register, please contact us at email@example.com.